Clinically established biodegradable long acting injectables: An industry perspective

Christian Isalomboto Nkanga; Andreas Fisch; Mazda Rad-Malekshahi; Marieta Duvnjak Romic; Birgit Kittel; Thomas Ullrich; Jing Wang; Rui Werner Maçedo Krause; Sabine Adler; Twan Lammers; Wim E Hennink; Farshad Ramazani

doi:10.1016/j.addr.2020.11.008

Clinically established biodegradable long acting injectables: An industry perspective

Christian Isalomboto Nkanga, Andreas Fisch, Mazda Rad-Malekshahi, Marieta Duvnjak Romic, Birgit Kittel, Thomas Ullrich, Jing Wang, Rui Werner Maçedo Krause, Sabine Adler, Twan Lammers, Wim E Hennink, Farshad Ramazani

Center for Chemico- and Bio-Medicinal Research (CCBR), Department of Chemistry, Rhodes University, P.O. Box 94, Grahamstown 6140, South Africa; Faculty of Pharmaceutical Sciences, University of Kinshasa, B.P. 212, Kinshasa, XI, Democratic Republic of the Congo; Technical Research and Development, Novartis Pharma AG, Basel 4002, Switzerland.
Technical Research and Development, Novartis Pharma AG, Basel 4002, Switzerland.
Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Novartis Institute for Biomedical Research, Novartis Pharma AG, Basel 4002, Switzerland.
Center for Chemico- and Bio-Medicinal Research (CCBR), Department of Chemistry, Rhodes University, P.O. Box 94, Grahamstown 6140, South Africa.

Research output: Contribution to journal › Review article › peer-review

Abstract

Long acting injectable formulations have been developed to sustain the action of drugs in the body over desired periods of time. These delivery platforms have been utilized for both systemic and local drug delivery applications. This review gives an overview of long acting injectable systems that are currently in clinical use. These products are categorized in three different groups: biodegradable polymeric systems, including microparticles and implants; micro and nanocrystal suspensions and oil-based formulations. Furthermore, the applications of these drug delivery platforms for the management of various chronic diseases are summarized. Finally, this review addresses industrial challenges regarding the development of long acting injectable formulations.

Original language	English
Pages (from-to)	19-46
Number of pages	28
Journal	Advanced Drug Delivery Reviews
Volume	167
DOIs	https://doi.org/10.1016/j.addr.2020.11.008
Publication status	Published - Dec 2020

Keywords

Long acting injectables
Extended release
Drug delivery
PLGA microparticles
Microspheres
Implants
In situ forming implants
Drug crystals
Oil-based formulations
Drug crystal suspensions

Access to Document

10.1016/j.addr.2020.11.008

1-s2.0-S0169409X20302179-mainFinal published version, 2.72 MBLicence: Taverne

Cite this

@article{eae715a82f9340b8a562cfe9e2a1d553,

title = "Clinically established biodegradable long acting injectables: An industry perspective",

abstract = "Long acting injectable formulations have been developed to sustain the action of drugs in the body over desired periods of time. These delivery platforms have been utilized for both systemic and local drug delivery applications. This review gives an overview of long acting injectable systems that are currently in clinical use. These products are categorized in three different groups: biodegradable polymeric systems, including microparticles and implants; micro and nanocrystal suspensions and oil-based formulations. Furthermore, the applications of these drug delivery platforms for the management of various chronic diseases are summarized. Finally, this review addresses industrial challenges regarding the development of long acting injectable formulations.",

keywords = "Long acting injectables, Extended release, Drug delivery, PLGA microparticles, Microspheres, Implants, In situ forming implants, Drug crystals, Oil-based formulations, Drug crystal suspensions",

author = "Nkanga, {Christian Isalomboto} and Andreas Fisch and Mazda Rad-Malekshahi and Romic, {Marieta Duvnjak} and Birgit Kittel and Thomas Ullrich and Jing Wang and Krause, {Rui Werner Ma{\c c}edo} and Sabine Adler and Twan Lammers and Hennink, {Wim E} and Farshad Ramazani",

year = "2020",

month = dec,

doi = "10.1016/j.addr.2020.11.008",

language = "English",

volume = "167",

pages = "19--46",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Clinically established biodegradable long acting injectables

T2 - An industry perspective

AU - Nkanga, Christian Isalomboto

AU - Fisch, Andreas

AU - Rad-Malekshahi, Mazda

AU - Romic, Marieta Duvnjak

AU - Kittel, Birgit

AU - Ullrich, Thomas

AU - Wang, Jing

AU - Krause, Rui Werner Maçedo

AU - Adler, Sabine

AU - Lammers, Twan

AU - Hennink, Wim E

AU - Ramazani, Farshad

PY - 2020/12

Y1 - 2020/12

N2 - Long acting injectable formulations have been developed to sustain the action of drugs in the body over desired periods of time. These delivery platforms have been utilized for both systemic and local drug delivery applications. This review gives an overview of long acting injectable systems that are currently in clinical use. These products are categorized in three different groups: biodegradable polymeric systems, including microparticles and implants; micro and nanocrystal suspensions and oil-based formulations. Furthermore, the applications of these drug delivery platforms for the management of various chronic diseases are summarized. Finally, this review addresses industrial challenges regarding the development of long acting injectable formulations.

AB - Long acting injectable formulations have been developed to sustain the action of drugs in the body over desired periods of time. These delivery platforms have been utilized for both systemic and local drug delivery applications. This review gives an overview of long acting injectable systems that are currently in clinical use. These products are categorized in three different groups: biodegradable polymeric systems, including microparticles and implants; micro and nanocrystal suspensions and oil-based formulations. Furthermore, the applications of these drug delivery platforms for the management of various chronic diseases are summarized. Finally, this review addresses industrial challenges regarding the development of long acting injectable formulations.

KW - Long acting injectables

KW - Extended release

KW - Drug delivery

KW - PLGA microparticles

KW - Microspheres

KW - Implants

KW - In situ forming implants

KW - Drug crystals

KW - Oil-based formulations

KW - Drug crystal suspensions

U2 - 10.1016/j.addr.2020.11.008

DO - 10.1016/j.addr.2020.11.008

M3 - Review article

C2 - 33202261

SN - 0169-409X

VL - 167

SP - 19

EP - 46

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

Clinically established biodegradable long acting injectables: An industry perspective

Abstract

Keywords

Access to Document

Fingerprint

Cite this